PRX and TEVA Related HeadlinesGo Back
- Needham & Company Maintains a 'Hold' on Par Pharmaceutical (PRX); Is Endo (ENDP) the 'Mystery Bidder'
- Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo
- Par Pharmaceutical (PRX) Peers On Watch After Deal (TEVA) (MYL) (WPI)
- Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Defending Core Fundamentals Despite Setback From Lovaza Litigation
- Amarin Corporation plc (AMRN) Ramps on Lovaza News
- Teva (TEVA), Par Pharma (PRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza